Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Study of humoral and cellular immunity in vaccinated with mRNA-1273.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Munksgaard Country of Publication: Denmark NLM ID: 8803400 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0463 (Electronic) Linking ISSN: 09034641 NLM ISO Abbreviation: APMIS Subsets: MEDLINE
    • Publication Information:
      Publication: Copenhagen : Munksgaard
      Original Publication: Copenhagen : Munksgaard, c1988-
    • Subject Terms:
      COVID-19*/prevention & control ; Vaccines*; 2019-nCoV Vaccine mRNA-1273 ; Antibodies, Viral ; BNT162 Vaccine ; COVID-19 Vaccines ; Humans ; Immunity, Cellular ; Immunity, Humoral ; Longitudinal Studies ; SARS-CoV-2
    • Abstract:
      The new vaccines against SARS-CoV-2 have raised a lot of expectations about their ability to induce immunity and the duration of this. This is the case of mRNA vaccines such as Moderna's mRNA-1273. Therefore, it is necessary to study the humoral and cellular immunity generated by these vaccines. Our objectives are determining what is the normal response of antibody production, and what is the level of protective antibodies and monitoring patients in case of subsequent infection with COVID-19. We present the first results of a longitudinal study of the humoral response in 601 health workers vaccinated with Moderna. The results show a humoral immunity at 90 days after the second dose of 100%, with a strong decrease between the levels of circulating anti-S IgG antibodies between days 30 and 90 post-vaccination. Observing a steeper decline in those who had higher titles at the beginning. In addition, we present a cellular response of 86% at three months after the second dose, which is related to low humoral response.
      (© 2022 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology.)
    • References:
      Euro Surveill. 2021 Feb;26(6):. (PMID: 33573712)
      Cell Host Microbe. 2021 Jul 14;29(7):1111-1123. (PMID: 34265245)
      Immunity. 2020 Dec 15;53(6):1281-1295.e5. (PMID: 33296685)
      Autoimmunity. 2013 Mar;46(2):83-101. (PMID: 23181381)
      Clin Exp Immunol. 2020 Nov;202(2):162-192. (PMID: 32935331)
      N Engl J Med. 2020 Dec 17;383(25):2427-2438. (PMID: 32991794)
      Lancet. 2021 Jan 9;397(10269):72-74. (PMID: 33306990)
      N Engl J Med. 2021 Sep 2;385(10):951-953. (PMID: 34260834)
      Nat Med. 2003 Sep;9(9):1131-7. (PMID: 12925846)
      Vaccine. 2016 Apr 12;34(17):2008-14. (PMID: 26954467)
      N Engl J Med. 2021 Jun 10;384(23):2187-2201. (PMID: 33882225)
      Clin Microbiol Rev. 2019 Mar 13;32(2):. (PMID: 30867162)
      Sci Transl Med. 2015 Apr 8;7(282):282ra48. (PMID: 25855494)
      Nat Rev Immunol. 2015 Mar;15(3):160-71. (PMID: 25698678)
      Lancet Infect Dis. 2020 Oct;20(10):1128. (PMID: 32979327)
      Cell. 2021 Jan 7;184(1):169-183.e17. (PMID: 33296701)
      Immunity. 2020 Oct 13;53(4):724-732.e7. (PMID: 32783919)
      MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1156-1162. (PMID: 34437524)
      N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
      Nature. 2021 Apr;592(7855):616-622. (PMID: 33567448)
      Biochem Biophys Res Commun. 2021 Jan 29;538:211-217. (PMID: 33190827)
      N Engl J Med. 2021 Jun 10;384(23):2259-2261. (PMID: 33822494)
      Eur Respir J. 2020 Aug 27;56(2):. (PMID: 32430429)
      Immunity. 1998 Mar;8(3):363-72. (PMID: 9529153)
      Cell Rep Med. 2021 Jun 15;2(6):100290. (PMID: 33969322)
      Nature. 2021 Feb;590(7844):E17. (PMID: 33469214)
      JAMA Intern Med. 2021 Dec 1;181(12):1660-1662. (PMID: 34398173)
      JAMA Netw Open. 2021 Sep 1;4(9):e2124331. (PMID: 34473262)
      Semin Immunopathol. 2019 Mar;41(2):239-249. (PMID: 30547182)
      PLoS One. 2020 Dec 31;15(12):e0244126. (PMID: 33382764)
      Cell Host Microbe. 2021 Jul 14;29(7):1033-1035. (PMID: 34265240)
      Nat Commun. 2020 Sep 17;11(1):4704. (PMID: 32943637)
      APMIS. 2022 May;130(5):261-269. (PMID: 35196403)
      Vacunas. 2021 Sep-Dec;22(3):173-179. (PMID: 34276267)
      Nat Commun. 2021 Mar 22;12(1):1813. (PMID: 33753738)
      Cell Host Microbe. 2021 Jul 14;29(7):1063-1075. (PMID: 34174992)
      N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
      Science. 2021 Sep 17;373(6561):1372-1377. (PMID: 34385356)
      Cell Host Microbe. 2021 Jul 14;29(7):1137-1150.e6. (PMID: 34133950)
    • Grant Information:
      Investigación y Desarrollo (I + D) del Sistema Andaluz de Salud (SAS); PI21/01708 Instituto de Salud Carlos III
    • Contributed Indexing:
      Keywords: Moderna vaccine; SARS-CoV-2; humoral response; mRNA vaccines; mRNA-1273 vaccine
    • Accession Number:
      0 (Antibodies, Viral)
      0 (COVID-19 Vaccines)
      0 (Vaccines)
      EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
      N38TVC63NU (BNT162 Vaccine)
    • Publication Date:
      Date Created: 20220223 Date Completed: 20220411 Latest Revision: 20220716
    • Publication Date:
      20231215
    • Accession Number:
      PMC9111507
    • Accession Number:
      10.1111/apm.13215
    • Accession Number:
      35196403